Lixte Biotechnology Holdings Inc (LIXT) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.61 (+3.44%), Market cap $0.06B, 52-week low–high $0.71 ~ $6.01.
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical and proton cancer therapy company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for
Financial statements, price targets, institutional (13F) holdings and related news for Lixte Biotechnology Holdings Inc are updated in real time on BlackAll Trade.
Lixte Biotechnology Holdings Inc trades at $3.61 (+3.44%). Real-time quotes and charts are available on BlackAll Trade.
Lixte Biotechnology Holdings Inc has a market cap of about $0.06B.
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical and proton cancer therapy company, focuses on identifying targets for cancer drug development, and developing and commercializing